

2023 - 1

Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

Belperio John A.¹, Nguyen Tuan², Lombardi David A.², Boguş Maxim³⁴, Moskalenko Valentyn⁵⁶, Singh Dave⁷, Haumann Brett⁸, Bourdet David L.², Kaufman Elad², Pfeifer Nathan D.², Thompson Corbin G.², Woo Jacky², Moran Edmund J.², Saggarr Rajeev²

¹ Ronald Reagan UCLA Medical Center, Los Angeles,

² Theravance Biopharma Inc, South San Francisco,

³ F.C.E. ARENSIA Exploratory Medicine,

⁴ Timofei Moşneaga Republican Clinical Hospital,

⁵ Kyiv City Clinical Hospital #12,

⁶ Brovary multidisciplinary clinical hospital,

⁷ University of Manchester,

⁸ Theravance Biopharma UK Limited, London

BMJ Open Respiratory Research

Vol. 10, / 2023 / ISSN 2052-4439

Disponibil online 15 August, 2023. Descarcări-1. Vizualizări-145



Copyright © 2011-2024 Instrumentul Bibliometric Național.

Institutul de Dezvoltare a Societății Informaționale.

Actualizat: 26.06.2024, accesat: 26.06.2024

Disponibil: <https://ibn.idsi.md>

